Edition:
United States

Eiger BioPharmaceuticals Inc (EIGR.OQ)

EIGR.OQ on NASDAQ Stock Exchange Global Market

12.00USD
15 Dec 2017
Change (% chg)

$-0.10 (-0.83%)
Prev Close
$12.10
Open
$12.10
Day's High
$12.15
Day's Low
$12.00
Volume
14,664
Avg. Vol
15,964
52-wk High
$13.95
52-wk Low
$6.15

Latest Key Developments (Source: Significant Developments)

‍Prosight Management reports a 6.9 percent passive stake in Eiger Biopharmaceuticals​
Thursday, 9 Nov 2017 09:07am EST 

Nov 9 (Reuters) - Eiger Biopharmaceuticals Inc :‍Prosight Management reports a 6.9 percent passive stake in Eiger Biopharmaceuticals​ as of Oct 31 - SEC filing.  Full Article

Eiger Biopharmaceuticals reports Q3 loss per share $1.10
Thursday, 9 Nov 2017 08:00am EST 

Nov 9 (Reuters) - Eiger Biopharmaceuticals Inc :Eiger Biopharmaceuticals reports third quarter 2017 financial results.Q3 loss per share $1.10.Q3 earnings per share view $-1.28 -- Thomson Reuters I/B/E/S.Eiger Biopharmaceuticals - ‍As of Sept 30, 2017, Eiger had cash, cash equivalents and short-term marketable securities of $32.3 million.Eiger Biopharmaceuticals Inc - ‍Company estimates its cash runway now extends into mid-2019​.  Full Article

EIGER BIOPHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK
Friday, 27 Oct 2017 09:17am EDT 

Oct 27 (Reuters) - Eiger Biopharmaceuticals Inc :EIGER BIOPHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 1.8 MILLION SHARES AT $10.00 PER SHARE, BEFORE UNDERWRITING DISCOUNTS & COMMISSIONS​.  Full Article

Eiger BioPharmaceuticals announces proposed public offering of common stock
Thursday, 26 Oct 2017 04:30pm EDT 

Oct 26 (Reuters) - Eiger BioPharmaceuticals Inc :Eiger BioPharmaceuticals announces proposed public offering of common stock.Eiger BioPharmaceuticals - ‍intends to use net proceeds of offering to fund clinical development of its portfolio of four product candidates​.  Full Article

Eiger says FDA orphan drug designation granted for pegylated interferon lambda in hepatitis delta virus infection
Tuesday, 5 Sep 2017 08:00am EDT 

Sept 5 (Reuters) - Eiger Biopharmaceuticals Inc ::Eiger announces FDA orphan drug designation granted for pegylated interferon lambda in hepatitis delta virus infection.  Full Article

Sphera Funds Management reports 5.35 pct passive stake in Eiger Biopharmaceuticals
Tuesday, 22 Aug 2017 01:35pm EDT 

Aug 22 (Reuters) - Sphera Funds Management Ltd::Sphera Funds Management Ltd reports a 5.35 percent passive stake in Eiger Biopharmaceuticals Inc as of August 17, 2017 - SEC Filing​.  Full Article

Eiger Biopharmaceuticals Q2 loss per share $1.33
Monday, 14 Aug 2017 08:00am EDT 

Aug 14 (Reuters) - Eiger Biopharmaceuticals Inc :Eiger Biopharmaceuticals reports second quarter 2017 financial results.Q2 loss per share $1.33.Q2 earnings per share view $-1.37 -- Thomson Reuters I/B/E/S.  Full Article

Eiger announces FDA fast track designation granted for pegylated interferon lambda
Thursday, 27 Jul 2017 08:00am EDT 

July 27 (Reuters) - Eiger Biopharmaceuticals Inc :Eiger announces fda fast track designation granted for pegylated interferon lambda in hepatitis delta virus infection.  Full Article

Eiger BioPharma announces sale of non-strategic assets to Theragene Pharma
Thursday, 29 Jun 2017 08:00am EDT 

June 29 (Reuters) - Eiger BioPharmaceuticals Inc ::Eiger BioPharmaceuticals announces sale of non-strategic assets to Theragene Pharmaceuticals.Eiger BioPharmaceuticals Inc - financial terms of agreement include a total upfront of $3.1 million in payments from Theragene to Eiger.Eiger BioPharmaceuticals Inc - additional financial terms are not being disclosed.Eiger BioPharmaceuticals Inc - Theragene has committed to repurchase $1.35 million of common stock paid to Eiger upon closing of a financing raise of $4 million or more.Eiger BioPharmaceuticals Inc - financial terms of agreement include expense reimbursement in addition to $2.85 million in Theragene common stock.Eiger BioPharmaceuticals Inc - financial terms of agreement include pre-specified clinical, regulatory milestones totaling $15 million, royalties on net sales, sublicensing milestone fees.  Full Article

Eiger reports additional positive phase 2 results from multiple-ascending dose study of exendin 9-39
Monday, 12 Jun 2017 08:00am EDT 

June 12 (Reuters) - Eiger Biopharmaceuticals Inc :Eiger reports additional positive phase 2 results from multiple-ascending dose study of exendin 9-39 in post-bariatric hypoglycemia patients at american diabetes association meeting in san diego.Sc exendin 9-39 liquid and lyophilized formulations were well tolerated with no related adverse events.Sc exendin 9-39 liquid and lyophilized formulations reduced postprandial hyperinsulinemic hypoglycemia.Sc exendin 9-39 liquid and lyophilized formulations reduced hypoglycemic symptoms.  Full Article

BRIEF-Eiger Biopharma Files For Mixed Shelf Of Up To $125 Mln

* EIGER BIOPHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $125 MILLION - SEC FILING Source text: (http://bit.ly/2nUkpvR) Further company coverage: